Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | MIF | P14174 | 13/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | GLA | P06280 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29066603 | 0.85 | ESR2 (0.61) | POLBHSD17B3ESR2MIFKDM4E | |
| SCHEMBL30405545 | 0.85 | HSD17B3 (0.65) | POLBHSD17B3ESR2MIFKDM4E | |
| SCHEMBL220708 | 0.85 | HSD17B3 (0.65) | POLBHSD17B3ESR2MIFKDM4E | |
| SCHEMBL16283606 | 0.83 | POLB (0.59) | POLBHSD17B3ESR2MIFKDM4E | |
| SCHEMBL28164061 | 0.83 | POLB (0.59) | POLBHSD17B3ESR2MIFKDM4E | |
| SCHEMBL12433441 | 0.81 | POLB (0.57) | POLBHSD17B3ESR2MIFKDM4E | |
| SCHEMBL2274941 | 0.81 | POLB (0.57) | POLBHSD17B3ESR2MIFKDM4E | |
| Anemarcoumarin A SCHEMBL774777 | 0.81 | POLB (0.77) | POLBHSD17B3ESR2MIFKDM4E | |
| SCHEMBL30002655 | 0.81 | POLB (0.57) | POLBHSD17B3ESR2MIFKDM4E | |
| SCHEMBL15082511 | 0.81 | HSD17B3 (0.59) | POLBHSD17B3ESR2MIFKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102924417-A | 4-(chloromethyl)-7-hydroxy coumarin compound and preparation method thereof | TIANJIN HEOWNS BIOCHEMISTRY TECHNOLOGY CO LTD | 2013-02-13 | — | — | CN | claimed |
| US-11761877-B2 | Hydrogel particles with tunable optical properties and methods for using the same | SLINGSHOT BIOSCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11747261-B2 | Hydrogel particles with tunable optical properties and methods for using the same | SLINGSHOT BIOSCIENCES, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11686661-B2 | Cytometric device hematology reference composition | SLINGSHOT BIOSCIENCES, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230152202-A1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20220260476-A1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20200400546-A1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-9714897-B2 | Hydrogel particles with tunable optical properties and methods for using the same | SLINGSHOT BIOSCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| CN-104059039-B | There is the fused ring compound of GPR40 function of receptors adjustment effects | 正大天晴药业集团股份有限公司 | 2017-03-15 | — | — | CN | disclosed |
| US-20160258856-A1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| CN-103228622-A | Agonists of gpr40 | CONNEXIOS LIFE SCIENCES PVT LTD | 2013-07-31 | — | — | CN | disclosed |
| US-20060183888-A1 | Pyrrolysine synthesis and modification | NIH - DEITR | 2006-08-17 | — | — | US | disclosed |
| US-20060166319-A1 | Charging tRNA with pyrrolysine | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183888-A1 | Pyrrolysine synthesis and modification | PTMS, QPCTL, DNPEP | POLB 1981/4885HSD17B3 4322/4885ESR2 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.